Drimva

inceptive

Accelerating impact through partnerships

$135K–$240K

Palo Alto, CA +1 · Full-time · Posted Jun 3, 2026

Location
Palo Alto, CA
Palo Alto, California, United States
Experience
5+ years; no alternatives stated.
Education
Ph.D. or M.S. in Molecular Biology, Biochemistry, Pharmacology, or a related life sciences field; MBA a plus.

About the job

Manages strategic siRNA and oligonucleotide partnerships, coordinating alliance governance and cross-functional execution to advance partnered drug discovery programs.

What you'll do

  • Manage day-to-day partner relationships, governance committees, milestones, deliverables, and escalations.
  • Coordinate internal teams and partners to execute programs and identify opportunities to expand collaborations.
  • Translate AI platform outputs and siRNA insights into partnership materials and support deal decisions.

What they ask for

  • Ph.D. or M.S. in Molecular Biology, Biochemistry, Pharmacology, or a related life sciences field.
  • 5+ years of experience in alliance management, business development, or strategic partnerships in biopharma or biotech.
  • Working knowledge of oligonucleotide therapeutics, particularly siRNA biology, mechanism of action, and drug development challenges.
  • Experience managing complex, multi-party research or licensing collaborations from initiation through program delivery.

Nice to have

  • MBA; familiarity with AI/ML applications in drug discovery.
  • Experience negotiating term sheets, CDAs, MTAs, or master research collaboration agreements; existing oligonucleotide therapeutics network.

Pay

$135K – $240K (base salary)

Tools

Linear, Notion, AI/ML

AI focus

Leverage a proprietary AI platform for partnerships and translate its outputs into collaboration narratives; familiarity with AI/ML drug discovery applications, including sequence-based target identification or predictive ADME/toxicity modeling.

Model-written summary · the original posting is authoritative

First seen Oct 13, 2026 · Last verified Nov 5, 2026 (UTC)